Real-world evidence of switching P2Y12 receptor–inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry

BACKGROUND: Potent P2Y(12) inhibitors are recommended for up to 12 months after percutaneous coronary intervention (PCI) in patients diagnosed with acute coronary syndrome (ACS). However, the prescription pattern is diverse in real world practice, which includes various switching between antiplatele...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Jeehoon, Han, Jung-Kyu, Yang, Han-Mo, Park, Kyung Woo, Kang, Hyun-Jae, Koo, Bon-Kwon, Choo, Eun Ho, Lee, Jong-Young, Park, Sang-Don, Lim, Young-Hyo, Kim, Hyung-Min, Heo, Ji-Hyun, Kim, Hyo-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827633/
https://www.ncbi.nlm.nih.gov/pubmed/36624388
http://dx.doi.org/10.1186/s12872-022-03034-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827633/
https://www.ncbi.nlm.nih.gov/pubmed/36624388
http://dx.doi.org/10.1186/s12872-022-03034-5

Ejemplares similares